---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-047678"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:53:58.844567+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma Q4 2024 net loss narrows to $9.5M; cash at $22.5M; pipeline pivots to autoimmune

## Summary
- Net loss of $9.5M in Q4 2024 ($0.13/share) vs $13.4M in Q4 2023; full year net loss $40.7M.
- Collaboration revenue $1.6M in Q4 vs $1.8M a year ago; full year rev $9.3M from Ono Pharma deal.
- R&D spend cut to $7.2M (Q4) from $10.9M; cash and equivalents $22.5M as of Dec 31, 2024.
- Regained worldwide rights to CUE-401 (autoimmune lead); prioritizing autoimmune over oncology.
- Appointed Lucinda Warren (CBO), Dr. Daniel Baker (Interim CDO), Dr. Pasha Sarraf (Board).

## SEC filing metadata
- accession: 0000950170-25-047678
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095017025047678/0000950170-25-047678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095017025047678/cue-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-047678
- JSON: https://secwatch.observer/filing/0000950170-25-047678.json
- Plain text: https://secwatch.observer/filing/0000950170-25-047678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.